Regional Account Manager -Pharma & Biotech, EMEA

Organization
NanoString Technologies
Job Location
Open to home base in Germany, UK, France, or Switzerland (Must live near airport)
United Kingdom
Salary
Competitive Comp Package
Benefits

Benefits include stock options and other competitive options depending on country.

Job Description

Job Summary:

The Regional Account Manager (RAM) will be accountable for revenue generation across EMEA by selling directly to customers primarily via face-to-face contact (Pharma and Biotech primarily).  Sell the nCounter Analysis System and associated consumables to support bioscience and medical research as well as diagnostics instrumentation.  The RAM will need to work very closely with the Field Applications Scientist, as well as Management, to leverage and develop key customer relationships. Responsible for devising direct sales plans and strategies.  Duties may require a high level of travel.

**Home base can be UK, France, Germany, Switzerland, preferably. Must have easy access to good international transport links**

Requirements
  • At least 3 years selling experience into the European Pharmaceutical and Biotech market segment. 
  • High level of travel required across EMEA.
  • Requires knowledge and understanding of Gene Expression analysis, miRNA and Copy Number Variation assays.
  • Requires a minimum of a bachelor's degree in a related science and may have an advanced degree, certification or additional professional training.  Typically requires six years of relevant experience.
  • Requires excellent communication skills, Verbal and written. Ability to conduct technical presentations
  • Ability to travel up to 75%.
  • Strong working knowledge of the sales process (quoting, purchasing, revenue recognition) as well as a good understanding of the Miller Heiman selling process and terminology.
About Our Organization

NanoString Technologies (NASDAQ:“NSTG”) provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 450 peer-reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity, reproducibility and precision. The company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic kit to be marketed through the company's diagnostics business. Leveraging the company’s innovative platform and proven development, regulatory and commercial expertise , NanoString has established a companion diagnostics capability to enable biopharmaceuticals partners to translate biomarker discoveries into clinically-relevant diagnostics, helping to bring the right therapy to the right patient at the right time.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.

A new survey from the Pew Research Center finds that half of women working in STEM have experienced gender discrimination at work.